What is Acesion Pharma?
Acesion Pharma is a biopharmaceutical company dedicated to pioneering novel therapies for the safe and effective treatment of atrial fibrillation, the most prevalent form of cardiac arrhythmia. The company's core strategy revolves around SK ion channel inhibition, a unique mechanism designed to enhance therapeutic efficacy and patient safety. By building a robust pipeline of potential best-in-class treatments, Acesion Pharma aims to significantly improve patient outcomes in cardiovascular care. Their target market includes healthcare providers and individuals affected by atrial fibrillation.
How much funding has Acesion Pharma raised?
Acesion Pharma has raised a total of $59.5M across 3 funding rounds:
Private Equity
$2.5M
Series A
$10M
Series B
$47M
Private Equity (2014): $2.5M with participation from Novo Seeds and Broadview Ventures
Series A (2016): $10M led by The Wellcome Trust and Novo A/S
Series B (2023): $47M supported by Alpha Wave Global, Global BioAccess Fund, Novo Holdings, and Canaan
Key Investors in Acesion Pharma
Alpha Wave Global
Alpha Wave Global is an investment firm that has participated in Acesion Pharma's Series B funding round.
Global BioAccess Fund
RM Global BioAccess Fund is an investment banking firm that focuses on fund management, specifically investing in transformative technologies aimed at addressing unmet medical needs in oncology, cardiovascular, CNS, and rare diseases. The firm partners with innovative companies to develop novel therapeutics and devices, providing capital to early-stage companies for IND submissions and clinical trials. Their investment strategy is centered on accelerating the development of new medicines to improve patient outcomes. The intended clients include companies in the healthcare sector that are working on groundbreaking medical solutions.
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation. The company was established in 1999 and is headquartered out of Hellerup, Denmark.
What's next for Acesion Pharma?
With the recent major strategic investment, Acesion Pharma is well-positioned to accelerate its development pipeline and clinical trials. This substantial backing, totaling $59.5M, indicates a strong market confidence in their innovative approach to treating atrial fibrillation. The company is expected to leverage this capital to advance its SK ion channel inhibitor programs, potentially bringing new therapeutic options to patients and healthcare providers. Future growth will likely involve further clinical validation and strategic partnerships to expand market reach and solidify its position in the cardiovascular therapeutics sector.
See full Acesion Pharma company page
